The management of brain metastases(BMs)has rapidly evolved in recent years[1].It is estimated that 20%-40%of cancer patients will develop BMs during their disease,while prevalence will probably grow thanks to the incr...The management of brain metastases(BMs)has rapidly evolved in recent years[1].It is estimated that 20%-40%of cancer patients will develop BMs during their disease,while prevalence will probably grow thanks to the increased efficacy of systemic treatments.Whole-brain radiotherapy has long been the first-line treatment for BMs.Large-scale international clinical trials conducted over the past decade have established that stereotactic radiotherapy(SRT)is the treatment of choice for the management of patients harboring up to 3-5 metastases with the compromise of increased distant brain failure(DBF)rates[2].Selection of patients and appropriate monitoring of patients remain a challenge.展开更多
文摘The management of brain metastases(BMs)has rapidly evolved in recent years[1].It is estimated that 20%-40%of cancer patients will develop BMs during their disease,while prevalence will probably grow thanks to the increased efficacy of systemic treatments.Whole-brain radiotherapy has long been the first-line treatment for BMs.Large-scale international clinical trials conducted over the past decade have established that stereotactic radiotherapy(SRT)is the treatment of choice for the management of patients harboring up to 3-5 metastases with the compromise of increased distant brain failure(DBF)rates[2].Selection of patients and appropriate monitoring of patients remain a challenge.
